Another lung cancer drug seem to work well

Since we’re on the topic of lung cancer, the experimental drug Eli Lilly acquired from Loxo Oncology for $8 billion seems to have been worth its while. Selpercatinib decreased tumors in about two out of three lung cancer patients by at least 30%, with the response lasting around a year and a half. Of course, the drug works only in patients who carry a specific gene alteration — about 2% of the patient population.

The drug’s efficacy has beaten the company’s own expectations, as one top exec told STAT’s Matthew Herper. 

Read more.